In 2024, diabetes medicine sales in Canada begin at $114.2 US Dollars PPP Per Capita, with forecasts indicating growth to $165.8 by 2028. This represents a steady annual increase, emphasizing the expanding market for diabetes medications. Year-on-year growth rates highlight a substantial upward trend from 2024, averaging approximately 9% annually as calculated by the Compound Annual Growth Rate (CAGR).

Future trends to watch for include:

The impact of new technological advancements in diabetes treatment and control.
Potential regulatory changes affecting market dynamics.
Expanding prevalence of diabetes among the Canadian population, driving demand for medication.